Fitzpatrick Jennifer 4
4 · Sionna Therapeutics, Inc. · Filed Dec 9, 2025
Insider Transaction Report
Form 4
Fitzpatrick Jennifer
Chief Legal Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-05$6.11/sh+10,250$62,628→ 10,250 total - Sale
Common Stock
2025-12-05$40.52/sh−10,250$415,330→ 0 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-12-05−10,250→ 61,185 totalExercise: $6.11Exp: 2034-07-14→ Common Stock (10,250 underlying)
Footnotes (3)
- [F1]This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on June 5, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.88 to $41.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- [F3]25% of the shares underlying this option vested on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.